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Introduction {#sec1}
============

Skeletal muscle is highly vascularized and myofibers are laced with a dense microvasculature. Numerous studies have reported the importance of vascularization in skeletal muscle function as well as the plasticity of vessels to adapt to the physiological demand ([@bib24]). The organization of the vascular bed in adult skeletal muscle is well understood, and a microvascular unit was described to comprise 5--10 capillaries located in between 3 and 4 adjacent myofibers ([@bib13], [@bib24]). This vascular organization is altered in muscle diseases characterized by an important muscle regeneration process, including those directly affecting the vessels ([@bib13], [@bib14]) or the myofibers ([@bib25]). Muscle regeneration relies on the capacities of satellite cells (SCs), the muscle stem cells, to activate and proliferate, giving rise to a population of transient amplifying myogenic precursor cells (MPCs) that express Pax7 and then the transcription factors Myf5 and MyoD ([@bib52]). Later on, MPCs exit the cell cycle, enter into terminal myogenic differentiation, and fuse to form new myofibers. A subset of MPCs does not differentiate and self-renews to replenish the SC pool ([@bib52]). Numerous studies have shown that the close microenvironment of SCs and MPCs is crucial for good implementation of adult myogenesis and skeletal muscle regeneration, including immune cells, notably macrophages ([@bib2], [@bib41]), and fibro-adipogenic precursor (FAPs) cells ([@bib21], [@bib46]).

Studies have demonstrated the importance of the interactions between the vessels and myogenic cells, besides the supply of oxygen and nutriments. *In vivo*, myonuclei ([@bib36]) and SCs ([@bib7]) are preferentially associated with vessels along the myofiber. In resting conditions, the number of capillaries surrounding a myofiber is highly correlated with the number of SCs associated with the same myofiber ([@bib7]). Specific subsets of peri-ECs exhibit some potent myogenic properties ([@bib34]) while other peri-ECs are involved in the maintenance of the quiescence of SCs ([@bib1]). During muscle regeneration, the vascular bed undergoes profound alterations, with increased number of capillaries, branching, and anastomosis ([@bib17]), associated with the activation of endothelial cells (ECs) ([@bib16]). ECs and SCs concomitantly proliferate after an injury *in vivo* ([@bib39]) and the two cell types cooperate *in vitro*. ECs stimulate MPC growth while MPCs exhibit angiogenic-like properties ([@bib7], [@bib12], [@bib38]). A series of growth factors were involved in these interactions, including vascular endothelial growth factor (VEGF), insulin growth factor (IGF) 1, platelet-derived growth factor (PDGF)-BB, hepatocyte growth factor (HGF), and basic fibroblast growth factor (bFGF) ([@bib3], [@bib4], [@bib5], [@bib7]).

While these studies show privileged interactions between ECs and MPCs in regenerating muscle, the impact of ECs on myogenesis and that of SCs/MPCs on vessels, as well as the underlying molecular mechanisms, is still not documented. Here, we aimed to demonstrate the spatiotemporal cellular coupling of myogenesis and angiogenesis during muscle regeneration by using various human cell coculture systems and an *in vivo* angiogenesis assay. We further investigated the molecular effectors at work by performing high-throughput kinetic analyses of genes expressed by ECs and SCs during skeletal muscle regeneration. Functional experiments identified three molecular regulators of myogenesis/angiogenesis coupling that are required for a proper skeletal muscle regeneration. Finally, we investigated the role of anti-inflammatory, or restorative, macrophages, which are present in regenerating muscle, at the time when myogenic differentiation and angiogenesis take place, by establishing a 3D triculture setup mimicking the complex cellular crosstalks at work during skeletal muscle regeneration.

Results {#sec2}
=======

ECs Stimulate *In Vitro* Myogenesis {#sec2.1}
-----------------------------------

Interactions between MPCs and ECs were investigated using primary human cells. Using a bicameral chemotaxis assay ([Figure 1](#fig1){ref-type="fig"}A1), we showed that ECs enhanced the mean MPC migration distance by 29% ([Figure 1](#fig1){ref-type="fig"}A1), as well as the number of migrating MPCs (+220%, not shown), therefore greatly enhancing the migrating distance of the whole MPC population (+306%) ([Figure 1](#fig1){ref-type="fig"}A2). EC-conditioned medium increased MPC proliferation by 64% ([Figure 1](#fig1){ref-type="fig"}B), and even more their myogenin expression (+95%), indicating their entry into terminal myogenesis ([Figure 1](#fig1){ref-type="fig"}C). Under these conditions, i.e., very low serum-containing medium, EC-conditioned medium had no impact on fusion of already differentiated myocytes (mononucleated myogenin expressing cells) ([Figure 1](#fig1){ref-type="fig"}D). Thus, ECs exhibited pro-myogenic properties by stimulating MPC migration, proliferation, and their terminal differentiation.Figure 1Pro-myogenic Properties of ECs(A) MPCs and ECs were seeded in two separate chambers whose walls were removed 12 hr later so that the two cell types faced each other, allowing migration toward each other over a 24 hr period. Black and white arrows indicate the migrating distance of an MPC and an EC, respectively. (A1) Mean individual MPC migration distance toward ECs (MPC/EC), (A2) total migration distance of the migrating MPCs. Control included migration of MPCs toward MPCs (MPC/MPC).(B and C) MPCs were cultured at low density with (EC-CM) or without (none) EC-conditioned medium. (B) Proliferating MPCs were counted as Ki67^pos^ cells (red, arrowheads). (C) Differentiating MPCs were counted as myogenin^pos^ (green, arrowheads) nuclei among desmin^pos^ cells.(D) Myocytes were cultured at high density with or without EC-CM. Myotubes (desmin^pos^, red, arrowheads) were counted according to their number of nuclei.Results are means ±SEM of six independent experiments. Bars, 50 μm. Blue, Hoechst. Mann-Whitney test was performed versus MPC/MPC (A), or none (C and D): ^∗^p \< 0.05, ^∗∗^p \< 0.01.

MPCs Promote *In Vitro* Angiogenesis {#sec2.2}
------------------------------------

MPCs enhanced mean EC migration by 30% ([Figure 2](#fig2){ref-type="fig"}A1), as well as the number of migrating ECs (+165%, not shown), therefore greatly enhancing the migration distance of the whole EC population (+200%) ([Figure 2](#fig2){ref-type="fig"}A2). MPC-conditioned medium had no effect on EC proliferation ([Figure 2](#fig2){ref-type="fig"}B). MPC angiogenic properties were investigated using a 3D angiogenic model that recapitulates the key stages of angiogenesis until the formation of an intraluminal compartment enabling the assessment of the full differentiation of the capillary structures that are formed ([@bib30]). ECs seeded alone formed poorly developed capillaries ([Figure 2](#fig2){ref-type="fig"}C, none). Thus, human dermal fibroblasts were layered on top of the gel as a positive control ([@bib9]). MPCs deposited on top of the gel (MPC ON in [Figure 2](#fig2){ref-type="fig"}C) exhibited a similar pro-angiogenic activity. When MPCs were seeded within the gel, the formation of capillaries was significantly stimulated in a dose-dependent way (MPC IN 50-100-250, [Figure 2](#fig2){ref-type="fig"}C1). Moreover, the presence of MPCs within the gel strongly increased the number of lumenized capillaries ([Figure 2](#fig2){ref-type="fig"}C2), indicative of a positive effect of MPCs on vessel maturation. The presence of myotubes was observed when MPCs were cocultured within the gel (arrows, [Figure 2](#fig2){ref-type="fig"}C) indicative of concomitant myogenesis and angiogenesis. Moreover, testing undifferentiated MPCs, differentiated mononucleated cells (myocytes), and fully differentiated multinucleated cells (myotubes) showed that the more myogenic cells were differentiated, the more they stimulated capillary elongation ([Figure 2](#fig2){ref-type="fig"}D1) and lumenization ([Figure 2](#fig2){ref-type="fig"}D2), highlighting a tight coordination between myogenesis and angiogenesis.Figure 2Pro-angiogenic Properties of MPCs(A) MPCs and ECs were cultured as described in [Figure 1](#fig1){ref-type="fig"}A1. (A1) Mean individual cell migration and (A2) total migration distance of ECs toward MPCs (EC/MPC) were measured. Control included migration of ECs toward ECs (EC/EC).(B) ECs were cultured with (MPC-CM) or without (none) MPC-conditioned medium. Proliferating ECs were counted as Ki67^pos^ cells (red, arrowheads) (blue, Hoechst).(C and D) 3D capillary formation assay. (C) Cytodex beads coated with GFP-ECs were seeded in 3D fibrin gels alone (none) or with fibroblasts on top of the gel (Fibro ON), MPCs on top (MPC ON), or inside (MPC IN) the gel at different concentrations (50,000, 100,000, or 250,000 cells/mL). Capillary length (C1) and lumenization (C2) were measured after 3 and 6 days of culture. Pictures show representative examples of beads at day 6 on phase contrast (upper panel) and fluorescence (lower panel) of the same field. Myotubes are indicated by white arrows. (D) A 3D angiogenesis assay was performed using undifferentiated myoblasts (MPCs), myocytes, or multinucleated myotubes seeded in the gel (100,000 cells/mL) and capillary length (D1) and lumenization (D2) were estimated. Pictures show representative examples of beads at days 3 and 6. Magnifications on the right show capillaries with lumen (arrows) and without lumen (arrowheads). MPC IN 100 triggered different effects on capillary length in C1 and D1 (but similar effects on lumenization in C2 and D2) likely due to different human primary cultures.Mann-Whitney test was performed versus EC/EC (A), none (B), fibroblasts (C), and MPCs (D): ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. Results are means ± SEM of six (A), five (B), five (C), and three (D) independent experiments. Bars, 100 μm.

MPCs Promote *In Vivo* Angiogenesis {#sec2.3}
-----------------------------------

*In vivo* angiogenic properties of MPCs were evaluated using the Matrigel plug assay, in which the development of capillary blood vessels from the host inside the plug correlates with the angiogenic property of molecules initially embedded into the plug ([@bib19]). The number of vessels (CD31^pos^ structures) ([Figures 3](#fig3){ref-type="fig"}A and 3B) detected in the plug was greatly increased (+755%) when MPCs were embedded into the plug, compared with plugs embedded with fibroblasts or containing no cells ([Figure 3](#fig3){ref-type="fig"}C). The CD31^pos^ structures formed functional capillaries since the hemoglobin content of the plug was increased by 93% in the presence of MPCs ([Figure 3](#fig3){ref-type="fig"}D). Accordingly, these vessels appeared well differentiated as they were surrounded by α-smooth muscle actin (SMA)-expressing cells, evocative of perivascular cells ([Figure 3](#fig3){ref-type="fig"}E). The high positive correlation observed between the presence of desmin^pos^ cells (myotubes) and of CD31^pos^ cells (vessels) ([Figure 3](#fig3){ref-type="fig"}F) confirmed the *in vitro* data and showed that myogenesis and angiogenesis are also coupled *in vivo*.Figure 3MPC Angiogenic Activity *In Vivo*(A--D) Matrigel plugs containing no cells (none), fibroblasts, or MPCs were injected subcutaneously into mice and were excised 3 weeks later. Representative pictures of plugs containing fibroblasts (A) or MPCs (B) stained for CD31 (red) and for desmin (green). Quantification of the presence of CD31^pos^ structures (C) and hemoglobin content (D) in the plug.(E) Representative picture of a plug containing MPCs stained for α-smooth muscle actin (SMA) (green).(F) Correlation of the number of CD31^pos^ (endothelium) and desmin^pos^ (myogenic) structures.Blue, Hoechst.Results are means ± SEM of five independent experiments. Mann-Whitney test was performed versus MPCs (C) or fibroblasts (D): ^∗^p \< 0.05; ^∗∗^p \< 0.01. Bars, 50 μm.

Molecular Analysis of Myogenesis/Angiogenesis Coupling {#sec2.4}
------------------------------------------------------

Microarray analysis of ECs and MPCs sorted at different time points (days 0, 2, 4, 8, after cardiotoxin injury) during muscle regeneration in mouse was performed. Purity of sorted cells was checked by immunocytochemistry performed on cytospin preparations ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1I). A total of 2,725 and 1,715 genes were significantly up- or downregulated in SCs and ECs, respectively, during muscle regeneration. For each cell type, differentially expressed genes were gathered into clusters according to their kinetics of expression ([Figure S2](#mmc1){ref-type="supplementary-material"}). Enrichment in gene ontologies (GOs) (cell process) was calculated for each cluster using DAVID software. SC clusters enriched for GOs related to angiogenesis (i.e., clusters 1 and 5 in [Figure S2](#mmc1){ref-type="supplementary-material"}A) and EC clusters enriched for myogenesis (i.e., clusters 2, 4, 5, 7 in [Figure S2](#mmc1){ref-type="supplementary-material"}B) were selected. Using Pathway Studio software, extracellular molecules present in these clusters were analyzed for their capacity to enhance angiogenesis or myogenesis enrichment in the gene clusters expressed by the other cell type (see strategy in [Figure S1](#mmc1){ref-type="supplementary-material"}). The screening gave rise to a series of molecules among which those expressed by both ECs and MPCs were selected ([Table S1](#mmc2){ref-type="supplementary-material"}). Most of these molecules were already shown to regulate myogenesis and angiogenesis, separately (e.g., *Ace*, *Adam12*, *Angpt2*, *Dcn*, *Efnb1*, *Il1b*, *Il6*, *Lgals1*, *Sparc*,...) or concomitantly during muscle regeneration (e.g., *Ccl2*, *Igf1*, *Spp1*) ([Table S1](#mmc2){ref-type="supplementary-material"}). Among the genes expressed by both ECs and MPCs during muscle regeneration that have not been deeply investigated and for which inhibitory tools were available, *Apln* (Apelin), *Postn* (Periostin), and *Osm* (Oncostatin M) were identified. Apelin (APLN) acts through APJ receptor, a G protein-coupled receptor, and is involved in angiogenesis. Oncostatin M is a member of the gp130/IL-6 cytokine family and exerts pleiotropic effects through OSM receptor (OSMR) in mouse and OSMR and leukemia inhibitory factor receptor in human. First identified in bone, Periostin (POSTN) seems to play an essential role in tissue remodeling in response to injury. *Apln*, *Postn*, and *Osm* showed differential profile expression during muscle regeneration, with a peak of expression at day 2 for *Apln* and *Osm* and a peak at day 4--8 for *Postn* ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Their cognate receptors were also expressed (except for POSTN, which interacts with multiple cell-surface receptors, including αvβ3-and αvβ5-integrins, therefore activating several pathways involved in cell adhesion and migration \[[@bib6]\]). Expression of the molecules and their receptors was confirmed by RT-qPCR in growing human MPCs and ECs *in vitro* ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

Apelin, Oncostatin M, and Periostin Stimulate *In Vitro* Myogenesis and *In Vivo* Angiogenesis {#sec2.5}
----------------------------------------------------------------------------------------------

Recombinant proteins were added to MPCs in a medium containing 5% fetal bovine serum (FBS) to mimic a complex microenvironment. [Figure 4](#fig4){ref-type="fig"}A shows that APLN stimulated MPC proliferation in a dose-dependent way (up to 112%, [Figure 4](#fig4){ref-type="fig"}A1) and their differentiation into myocytes (up to 121%, [Figure 4](#fig4){ref-type="fig"}B1). Moreover, it stimulated the fusion of differentiated myocytes (up to 78%, [Figure 4](#fig4){ref-type="fig"}C1). Similar results were obtained with OSM, which was shown, for some concentrations, to stimulate the three steps of *in vitro* myogenesis (up to 187, 141, and 98%, respectively; [Figures 4](#fig4){ref-type="fig"}A2, 4B2, and 4C2). POSTN did not affect MPC proliferation ([Figure 4](#fig4){ref-type="fig"}A3), but it promoted their differentiation (63%, [Figure 4](#fig4){ref-type="fig"}B3) and myocyte fusion into myotubes (55%, [Figure 4](#fig4){ref-type="fig"}C3) in a dose-dependent manner, in accordance with the later expression of *Postn* during skeletal muscle regeneration ([Figure S3](#mmc1){ref-type="supplementary-material"}). These results indicate that APLN, OSM, and POSTN support myogenesis.Figure 4APLN, OSM, and POSTN Gain-of-Function Experiments(A--C) Human MPCs were treated with various concentrations of APLN (A1, B1, and C1), OSM (A2, B2, and C2), and POSTN (A3, B3, C3) (1--1,000 nM, 5--100 mg/mL, and 0.1--10 μg/mL, respectively). (A1--A3) MPC proliferation was evaluated using EdU labeling (red). (B1--B3) MPC differentiation was evaluated using labeling for desmin (red) and myogenin (green, arrowheads). (C1--C3) Fusion of differentiated myocytes was evaluated after immunolabeling for desmin (red). Arrowheads show myotubes.(D) Matrigel plug assay was performed using MPCs with or without recombinant APLN (10 nM), OSM (50 ng/mL), or POSTN (5 μg/mL). Vessel structures were quantified after CD31 (red) labeling.Blue, Hoechst. Mann-Whitney test was performed versus none: ^∗^p \< 0.05; ^∗∗^p \< 0.01. Results are means ± SEM of six and seven independent *in vitro* and *in vivo* experiments, respectively. Bars, 50 μm. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

[Figure 4](#fig4){ref-type="fig"}D shows that the presence of APLN, OSM, or POSTN strongly supported the development of blood vessels in the Matrigel plug assay (+196%, +230%, and 58%, respectively).

Apelin, Oncostatin M, and Periostin Directly Control Myogenesis/Angiogenesis Coupling {#sec2.6}
-------------------------------------------------------------------------------------

A 3D angiogenesis assay (using GFP-ECs) was used with red fluorescent protein (RFP)-labeled MPCs to analyze myotube formation. We compared the formation of capillaries and myotubes in the absence of MPCs and ECs, respectively. ECs cultured alone formed short capillaries with no lumen while the presence of MPCs strongly increased both processes ([Figures 5](#fig5){ref-type="fig"}A and 5C). Inversely, while MPCs were capable of fusion when cultured alone in the 3D gel, the presence of ECs strongly increased myotube formation (+180%) ([Figure 5](#fig5){ref-type="fig"}E), confirming the reciprocal stimulation of the two cell types. Blocking either APLN, OSM, or POSTN (antibodies/inhibitors were added within the gel) strongly inhibited capillary morphogenesis, including capillary elongation (−10%, −15%, −22%, respectively) ([Figures 5](#fig5){ref-type="fig"}A and 5B) and lumenization (−36%, −39%, −38%, respectively) ([Figures 5](#fig5){ref-type="fig"}C and 5D), as well as myotube formation (−59%, −49%, −74%, respectively) ([Figures 5](#fig5){ref-type="fig"}E and 5F). Blocking antibodies did not fully blunt the stimulated angiogenesis and myogenesis, suggesting that other factors are involved. Adding IgGs or the blocking antibodies to ECs cultured alone did not affect the weak capillary formation, indicating a specific effect of these molecules on MPC-driven capillarization and lumenization ([Figures 5](#fig5){ref-type="fig"}A and 5C). Adding blocking antibodies to MPCs cultured alone inhibited myotube formation, indicative of an autocrine activity ([Figure 5](#fig5){ref-type="fig"}E). These results demonstrate the direct involvement of APLN, OSM, and POSTN in myogenesis/angiogenesis coupling, in addition to an autocrine effect occurring in MPCs.Figure 5APLN, OSM, and POSTN Loss-of-Function Experiment on Myogenesis/Angiogenesis CouplingThe 3D assay used EC-GFP and RFP-MPCs that were embedded in the gel together or alone. In some experiments, IgGs, APLN receptor inhibitor ML221 (16 μM), anti-OSM, or anti-POSTN blocking antibodies (50 and 40 μg/mL) were added. Six days later, capillary length (A), lumenization (C), and myotube fusion (E) were evaluated. On the right, pictures present examples of capillary elongation (B), capillary lumenization (green, arrows) (D), and myotube formation (red, arrowheads) (F) in EC + MPC conditions with or without the inhibitors. Results are means ± SEM of at least three independent experiments. Mann-Whitney test was performed versus EC + MPC: ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; and versus MPC + IgG: \$p \< 0.05; \$\$p \< 0.01. Bars, 100 μm. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Restorative Macrophages Stimulate Myogenesis/Angiogenesis Coupling {#sec2.7}
------------------------------------------------------------------

While the above molecular analysis was focused on ECs and SCs to demonstrate myogenesis/angiogenesis coupling, it is likely that other cell types may express a variety of molecules involved in this process. Macrophages and FAPs develop close interactions with MPCs ([@bib21], [@bib41]), and they are known to promote angiogenesis under some conditions ([@bib18], [@bib32]). RT-qPCR analysis on fluorescence-activated cell sorted populations in regenerating mouse muscle ([Figure S4](#mmc1){ref-type="supplementary-material"}A) showed that *Apln* was mainly expressed by ECs (and to a lesser extent by SCs and FAPs), that *Osm* was mainly expressed by macrophages (and to a lesser extent by SCs), while *Postn* was mainly expressed by FAPs, although the four cell types did express the molecule at late stages of skeletal muscle regeneration ([Figures S4](#mmc1){ref-type="supplementary-material"}B, and [6](#fig6){ref-type="fig"}A--6C). Because FAPs have not been well characterized in human muscle and thus cannot be tested in *in vitro* models, the role of macrophages was investigated in the 3D assay. For this purpose, macrophages were seeded on top of the gel ([Figure 6](#fig6){ref-type="fig"}D), after having been activated by interleukin (IL)-4, to trigger alternative activation status, which is known to promote both myogenesis ([@bib41]) and angiogenesis ([@bib20]). Macrophages were also activated with IL-10/dexamethasone, which induces an anti-inflammatory status ([@bib2], [@bib41]) closer to that of restorative macrophages in regenerating muscle ([@bib47]). [Figures 6](#fig6){ref-type="fig"}E--6I shows that IL-4 and IL-10 anti-inflammatory macrophages stimulated the formation (+25% and +22%) of lumenized (+26% and +31%) capillaries by ECs and that of myotubes by MPCs (+49% and +29%). Blocking OSM blunted the stimulating effect of anti-inflammatory macrophages on capillary elongation (−13%) and severely inhibited their lumenization (−60%) ([Figures 6](#fig6){ref-type="fig"}E--6G) and the formation of myotubes (−68%) ([Figures 6](#fig6){ref-type="fig"}H and 6I), accounting for an inhibitory effect on macrophages and on ECs and MPCs as shown in [Figure 5](#fig5){ref-type="fig"}. These results indicate that anti-inflammatory macrophage-derived OSM regulates myogenesis/angiogenesis coupling.Figure 6Effect of Macrophages on Myogenesis/Angiogenesis Coupling(A--C) Expression of *Apln* (A), *Osm* (B), and *Postn* (C) by ECs, SCs, macrophages (MP), and FAPs at day 2 and 4 of regeneration, as described in [Figure S4](#mmc1){ref-type="supplementary-material"}.(D, E, G, and I) 3D assay was performed with macrophages previously activated with interleukin (IL)-4 or IL-10/dexamethasone (DEX) layered on top of the gel (D). Six days later, capillary length (E), lumenization (G), and myotube formation (I) were quantified. In some experiments, anti-OSM blocking antibodies (50 μg/mL) were added.(F and H) Representative pictures with capillary lumen formation (green, arrows) and myotube formation (red, arrowheads).Results are means ± SEM of four to six independent experiments. Mann-Whitney test was performed versus none: ^∗^p \< 0.05; and versus Mp + IL10: \$p \< 0.05. Bars, 100 μm.

Apelin, Oncostatin M, and Periostin Are Required for Myogenesis and Angiogenesis during Skeletal Muscle Regeneration {#sec2.8}
--------------------------------------------------------------------------------------------------------------------

*In vivo* relevance of the role of APLN, OSM, or POSTN in myogenesis/angiogenesis coupling during skeletal muscle regeneration was evaluated in loss-of-function experiments. Because the molecules are secreted by several cell types, cell-specific KO models would not provide information. Therefore, experiments were performed using blocking antibodies or inhibitors injected intramuscularly at the time of the peak of expression of the molecules ([Figure S3](#mmc1){ref-type="supplementary-material"}) (days 2--3 after cardiotoxin injury for APJ receptor antagonist \[ML221\] and anti-OSM antibodies and days 3--4 for anti-POSTN antibodies). Analysis at day 8 after injury included several criteria assessing the efficacy of myogenesis, as well as the capillarization of the myofibers assessing the efficacy of angiogenesis. Because APLN is considered to be the only ligand for APJ and APJ to be the only receptor for APLN, we considered that antagonizing APJ receptor mimics APLN blockade ([@bib22]). APLN inhibition led to a decrease of the number of myogenin^pos^ cells (−28%, [Figure 7](#fig7){ref-type="fig"}A) as well as the number of nuclei/fiber (−20%, [Figure 7](#fig7){ref-type="fig"}B) and of embryonic myosin heavy chain (MyH3)^pos^-regenerating myofibers (−31%, [Figure 7](#fig7){ref-type="fig"}C), indicative of reduced myogenic differentiation, fusion, and regeneration processes, respectively. As a result, the cross-sectional area (CSA) of the regenerating myofibers was smaller (−26%, [Figure 7](#fig7){ref-type="fig"}E). OSM inhibition induced a decrease in the number of both myogenin^pos^ cells (−31%, [Figure 7](#fig7){ref-type="fig"}A), nuclei/fibers (−13%, [Figure 7](#fig7){ref-type="fig"}B), MyH3^pos^ myofibers (−28%, [Figure 7](#fig7){ref-type="fig"}C), SCs (Pax7^pos^)/fiber (−25%, [Figure 7](#fig7){ref-type="fig"}D), and CSA of regenerating myofibers (−21%, [Figure 7](#fig7){ref-type="fig"}E). Similarly, inhibition of POSTN induced a decrease in all parameters (−60% of myogenin^pos^ cells \[[Figure 7](#fig7){ref-type="fig"}A\], −15% of the number of nuclei/fiber \[[Figure 7](#fig7){ref-type="fig"}B\], −27% of MyH3^pos^ myofibers \[[Figure 7](#fig7){ref-type="fig"}C\], −25% of SCs/fiber \[[Figures 7](#fig7){ref-type="fig"}A and 7D\], −14% of CSA \[[Figure 7](#fig7){ref-type="fig"}E\]). Finally, capillarization of the myofibers (i.e., the number of vessels/regenerating myofiber) was decreased in all conditions (−22%, −23%, and −20% upon APLN, OSM, and POSTN inhibition, respectively) ([Figure 7](#fig7){ref-type="fig"}F). Collectively, these results show the requirement of the three secreted effectors in the control of the coupling of angiogenesis and myogenesis, which is required to achieve skeletal muscle regeneration.Figure 7*In Vivo* APLN, OSM, and POSTN Loss-of-Function Experiments during Skeletal Muscle RegenerationTibialis anterior muscles were injected with cardiotoxin. APLN receptor inhibitor (16 μM) and anti-OSM blocking antibodies (5 μg) were injected intramuscularly at days 2 and 3 post injury, while anti-POSTN blocking antibodies (5 μg) were injected intramuscularly at days 3 and 4 post injury. Muscles were recovered at day 8. The following criteria were evaluated: (A) number of myogenin^pos^ cells/mm^2^ (in pictures myogenin is green); (B) number of nuclei/fiber (in pictures laminin is green); (C) number of embyronic myosin heavy chain (MyH3)^pos^ fibers (in pictures MyH3 is red); (D) number of Pax7^pos^ (SCs)/fiber (in pictures Pax7 is green \[arrowheads\] and laminin is red); (E) cross-sectional area (CSA) of the regenerating myofibers (H&E staining); (F) number of vessels/myofiber (in pictures CD31 is red and laminin is green). Blue, Hoechst. Bars, 50 μm. Mann-Whitney test was performed versus PBS for Ab-OSM and Ab-POSTN and versus PBS-DMSO for Inh-APLN: ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. Results are means ± SEM of six independent experiments.

Discussion {#sec3}
==========

Our study demonstrates the functional interactions between ECs and MPCs underlying myogenesis/angiogenesis coupling during skeletal muscle regeneration. The two cell types reciprocally stimulated each other to promote angiogenesis and myogenesis *in vivo* and *in vitro*, showing that these two biological processes are coupled. Molecular profiling of ECs and SCs sorted from regenerating muscle allowed the identification of three effectors, APLN, OSM, and POSTN, that were shown to stimulate myogenesis/angiogenesis coupling and to be required for muscle regeneration. Furthermore, we described restorative macrophages as stimulators of myogenesis/angiogenesis coupling, notably through the secretion of OSM.

Previous studies identified bilateral relationships between MPCs and ECs ([@bib7], [@bib38]). However, the present work identifies which steps of myogenesis are specifically controlled by ECs and dissects the pro-angiogenic properties of MPCs. Indeed, the 3D assay we used here encompasses the sequential steps of angiogenesis, recapitulating proliferation, sprouting, and lumen formation observed *in vivo*, which is not the case in the classic Matrigel *in vitro* assay ([@bib30]). These results, coupled to the strong vessel formation in the *in vivo* Matrigel plug assay, definitively establish MPCs as pro-angiogenic cells. Notably, differentiated myocytes and myotubes strongly stimulated capillary morphogenesis. The analysis of cells cultured alone in the 3D model indicated that some weak autocrine activity drove the formation of short immature capillaries by ECS. MPCs alone formed myotubes but about 2-fold less efficiently than when ECs were present. This suggests that while an autocrine effect ensures basal myogenesis and angiogenesis, paracrine activities between ECs and MPCs strongly stimulate both processes, demonstrating the existence of a functional coupling of myogenesis with angiogenesis and explaining the previously observed concomitance of the two processes in regenerating muscle ([@bib39]).

Few studies investigated the molecular cross-talk between ECs and MPCs. EC-derived IGF-1, HGF, bFGF, PDGF-BB, and VEGF stimulate MPC growth *in vitro* ([@bib7], [@bib38]) while Gli3, a Hedgehog (Hh) transcription factor, controls the cross-talk during ischemic muscle repair ([@bib37]). Here, we restricted our transcriptomic analysis on effectors secreted by both ECs and SCs during skeletal muscle regeneration. Among the list ([Table S1](#mmc2){ref-type="supplementary-material"}), several effectors were involved in the regulation of myogenesis or angiogenesis or in skeletal muscle regeneration, such as Osteopontin ([@bib40]), urokinase type plasminogen activator ([@bib28]), Galectin 1([@bib11]), IL-6 ([@bib42]), and IGF-1 ([@bib7], [@bib20]). The screen identified three effectors, APLN, OSM, and POSTN, which were shown to stimulate myogenesis *in vitro* and angiogenesis *in vivo* in gain-of-function experiments. Moreover, blockade of these factors in the 3D coculture system strongly inhibited the formation of both myotubes and capillaries. Their blockade *in vivo* altered myogenesis and reduced angiogenesis in the regenerating muscle. The direct impact of APLN, OSM, and POSTN on both myogenesis and angiogenesis is thus necessary for driving efficient muscle regeneration.

The APLN/APJR axis is a known regulator of EC proliferation, sprouting, angiogenesis, vessel maturation, and size ([@bib31]). Our results identify a new function for APLN as a potent stimulator of myogenesis and confirmed its role in angiogenesis during tissue repair.

Matricellular POSTN expression is upregulated during myogenic differentiation *in vitro* ([@bib33]), in accordance with the expression profile we observed in SCs sorted from regenerating muscle. Consistently, POSTN stimulated the last steps of myogenesis, including differentiation and fusion. POSTN directly stimulated angiogenesis *in vivo*, in accordance with its positive effect on angiogenesis after limb ischemia ([@bib23]). *In vivo*, POSTN was previously observed around newly forming myofibers, suggesting secretion by interstitial cells ([@bib33]). We showed that FAPs and SCs were the main providers of POSTN. Unfortunately, FAPs have not been characterized in normal human muscle yet so further *in vitro* investigations were not feasible.

The role of OSM in myogenesis has been documented in one report that indicates that OSM (ranging from 0.1 to 20 ng/mL) inhibits myogenesis of murine cells, through gp130/OSMR and the JAK1/STAT1/STAT3 pathway ([@bib51]). The present study utilized higher doses of OSM (from 5 to 200 ng/mL) and human MPCs, which respond to OSM through both gp130/LIFR and gp130/OSMR receptors ([@bib45]). In this context, OSM stimulated all steps of myogenesis *in vitro*. Although dissecting the effects of OSM on each step of myogenesis would require a study in itself, we may assume that different OSM concentrations have, in combination with the FBS compounds present in the culture, various effects on MPCs. Some molecules were previously reported to oppositely stimulate MPC proliferation depending on their concentration (e.g., tumor necrosis factor alpha \[TNF-α\]; [@bib27]), and some molecules trigger opposite effects on different cell populations within the MPC culture (e.g., Angiopoetin-1 induces both self-renewal and differentiation; [@bib1]). Similar contrasting results have been reported for the effects of OSM on angiogenesis, reporting inhibitory ([@bib43]) and stimulating effects ([@bib48], [@bib49]). OSM effects certainly depend on its local concentration in the close environment, which may explain the discrepancy between these studies. However, our *in vitro* and *in vivo* loss-of-function studies clearly showed inhibition of both myogenesis and angiogenesis.

Macrophages were the main producers of OSM during skeletal muscle regeneration, as shown in other repairing tissues ([@bib10], [@bib15]). *Osm* expression is higher in recovery than in inflammatory macrophages (gene expression analysis in [@bib47]). Accordingly, blocking OSM inhibited the myogenesis/angiogenesis coupling induced by restorative macrophages in the 3D *in vitro* assay. Our previous work identified anti-inflammatory/restorative macrophages as supportive cells for MPC differentiation and fusion and as required for efficient muscle regeneration ([@bib2], [@bib29], [@bib41]). Macrophage angiogenic properties are less well documented in tissue repair, since they may secrete both pro-angiogenic or angiostatic factors ([@bib35]). Anti-inflammatory macrophages were shown to be more angiogenic than their pro-inflammatory counterparts ([@bib20]) but other studies reported an anti-angiogenic role of IL-4-activated macrophages ([@bib50]) and pro-angiogenic activity of pro-inflammatory macrophages ([@bib44]). Physical interactions between macrophages and ECs seem important in the branching during angiogenesis sprouting ([@bib44]) or "bridging sprouts" ([@bib8]). *In vivo,* animals deficient in 5′-AMP-activated protein kinase (AMPK) α1 in macrophages exhibit reduced remodeling of collateral arterioles after femoral artery ligation ([@bib53]), which may be explained by the defect in the acquisition of the restorative phenotype we previously reported ([@bib29]). Still *in vivo*, reduced macrophage infiltration in the injured muscle is associated with reduced angiogenesis ([@bib32], [@bib54]).

These results highlight the complexity of the cellular interactions that occur during tissue repair and reveal restorative macrophages as playing key roles in orchestrating concomitant parenchyma recovery (myogenesis and myofiber fusion) ([@bib41]), vascular bed recovery (angiogenesis), as well as matrix remodeling (through their action on FAPs; [@bib26]), to promote efficient skeletal muscle regeneration.

Experimental Procedures {#sec4}
=======================

Human MPC Culture {#sec4.1}
-----------------

Human MPCs were isolated from normal adult skeletal muscle samples according to French legislation (protocol registered at the Agence de la Biomedecine \#DC-2009-944) as previously described ([@bib41]). Conditioned medium was recovered after 24 hr in advanced RPMI 1640 medium (Gibco) containing 0.5% FBS. Differentiated myocytes were obtained after 72 hr of culture in HAMF12 medium containing 5% FBS. Myotubes were obtained from 72 hr cultures of myocytes. In some experiments, MPCs were transduced with RFP lentivirus.

Human Umbilical Vein Endothelial Cell Culture {#sec4.2}
---------------------------------------------

Human umbilical vein endothelial cells (HUVECs) were obtained from Promocell and cultured in ECGM-2 complete medium (Promocell). They were transduced with GFP lentivirus. Conditioned medium was recovered after 24 hr culture in advanced RPMI 1640 medium containing 0.5% FBS.

Migration Assay {#sec4.3}
---------------

Migration was performed using two-chamber Ibidi inserts (Ibidi GmbH). Each chamber was filled with MPCs or for 8--12 hr. Silicone walls were removed, and the gap between the two cell types was imaged at 0 and 24 hr.

Proliferation Assay {#sec4.4}
-------------------

Cells were seeded in multi-well plates and conditioned medium of the other cell type was added for 24 hr in the absence or presence of recombinant proteins. Ki67 immunolabeling or ethinyl deoxyuridine (EdU) staining was then performed.

Myogenic Differentiation {#sec4.5}
------------------------

HUVEC-conditioned medium was added to MPCs in the presence or the absence of recombinant proteins for 72 hr. Myogenin immunolabeling was performed.

Myogenic Fusion {#sec4.6}
---------------

HUVEC-conditioned medium was added for 72 hr on myocytes in the presence or absence of recombinant proteins. Desmin immunolabeling was performed.

3D *In Vitro* Angiogenesis Assay {#sec4.7}
--------------------------------

HUVEC-GFPs were combined with the cytodex beads and combined in the pre-gel solution as described previously ([@bib9]). MPCs, myocytes, or myotubes were added to the pre-gel. In some experiments, ECs or MPCs were seeded alone, and IgG, blocking antibodies, or inhibitors were added to the pre-gel. Human dermal fibroblasts (NHDF, Promocell) or MPCs or macrophages were seeded on top of the gel. The cells were cultured in EndoGro medium for up to 6 days.

*In Vivo* Muscle Regeneration {#sec4.8}
-----------------------------

Tibialis anterior muscle was injected with cardiotoxin and recovered for histological analysis at day 8 as described previously ([@bib29]). In some experiments, blocking antibodies or inhibitors were injected intramuscularly. Muscle cryosections were immunolabeled using anti-laminin, CD31, Ki67, Pax7, Myogenin, and MyH3 antibodies.

*In Vivo* Angiogenesis Assay {#sec4.9}
----------------------------

Adult male C57BL/6 mice were bred and used in compliance with French and European regulations. The principal investigators are licensed for these experiments, and the protocols were approved by local Animal Care and Use Committee and the French Ministery of Agriculture. Murine MPCs were cultured as described previously ([@bib29]). NIH3T3cells were cultured in DMEM containing 15% FBS. Cells were embedded in cold Matrigel and 500 μL of the mix was injected subcutaneously in 4- to 6-week-old male C57BL/6 mice. In some experiments, recombinant proteins were added. After 21 days, mice were euthanized, and plugs were recovered and fixed. Sections were treated with anti-CD31, desmin, and α-SMA antibodies. Functional angiogenesis inside the plug was evaluated as the amount of hemoglobin using Drabkin\'s reagent.

Cell Sorting from Regenerating Muscle {#sec4.10}
-------------------------------------

Single-cell suspensions were obtained from muscles by enzymatic digestion. ECs, SCs, macrophages, and FAPs were isolated using anti-CD45 PE, F4-80 APC-Cy7, CD34-FITC, Sca1-eFluor 605 or PerCP-Cy5.5, α7-integrin-APC, CD31-eFluor 450, and PDGFRα (CD140a) PE-Cy7 antibodies.

Transcriptomic Analysis {#sec4.11}
-----------------------

Total RNAs were extracted from sorted ECs or MPCs using an RNeasy Mini Kit (QIAGEN). RNA integrity was checked on an Agilent Bioanalyzer 2100. Global expression data were obtained using Affymetrix GeneChip Mouse Gene 2.0 ST arrays. The microarray data are publicly available (GEO: [GSE103684](ncbi-geo:GSE103684){#intref0010}). Data were robust multichip average normalized and were first controlled and analyzed in an unsupervised way by principal component analysis, and a one-way ANOVA was applied to extract DEGs using PartekGS software. Cluster analysis and enrichment were made using DAVID and Pathway Studio software (the strategy is presented in [Figure S1](#mmc1){ref-type="supplementary-material"}J). A list of genes expressed by both ECs and MPCs was finalized ([Table S1](#mmc2){ref-type="supplementary-material"}).

Statistics {#sec4.12}
----------

All experiments were performed in at least three independent experiments, i.e., different primary cultures or different animals. The exact number of experiments and statistical significance are given in the figure legends. Results are expressed as means ± SEM. Means were compared using Mann-Whitney or two-way ANOVA and Sidak post tests.
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